SCHEMBL26293248

SCHEMBL26293248

C[C@H](CC(=O)NC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)COc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.45
ALPI P09923 2/20 0.45
ALPG P10696 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
ALOX15 P16050 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 2/20 0.41
HPGD P15428 2/20 0.40
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26293249 0.81 ALDH1A1 (0.38) NPC1RAB9ALMNAMAPTKMT2A
SCHEMBL26293897 0.80 NPC1 (0.51) NPC1RAB9ALMNACASP3SENP7
SCHEMBL26292979 0.80 APAF1 (0.42) RAB9ALMNAMAPTHPGDGAA
SCHEMBL12038615 0.80 APAF1 (0.42) RAB9ALMNAMAPTHPGDGAA
SCHEMBL26293357 0.79 ESRRB (0.47) MAPTKMT2A
SCHEMBL15249334 0.79 ESRRB (0.47) MAPTKMT2A
SCHEMBL30511407 0.79 HDAC8 (0.48) ALPLALPIALPGNPC1LMNA
SCHEMBL16743931 0.79 MAPT (0.41) LMNAMAPTKMT2AMEN1HPGD
SCHEMBL26294391 0.77 MAPT (0.40) LMNAMAPTKMT2AHPGD
SCHEMBL19871023 0.77 MAPT (0.40) LMNAMAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 ALPL 2153/4885ALPI 67/4885ALPG 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.